News Channels

28 Sep 2017 OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells
28 Sep 2017 Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS)
28 Sep 2017 Moderna Announces Publication in Molecular Therapy Characterizing Potent Immune Response Generated by Its mRNA Prophylactic Vaccines
28 Sep 2017 Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
28 Sep 2017 Tricida Initiates Phase 3 Study of TRC101 for the Treatment of Metabolic Acidosis Associated With Chronic Kidney Disease
28 Sep 2017 Takeda and SGC Announce a Collaboration Agreement Using Patient Tissue-Based Assays for Clinical Target Validation in Inflammatory Bowel Disease
28 Sep 2017 Intarcia Provides Corporate Update
28 Sep 2017 AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Amgen
28 Sep 2017 Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome
28 Sep 2017 Eligo Bioscience Secures $20 Million Series A from Khosla Ventures and Seventure to Bring Precision Medicine to the Microbiome
28 Sep 2017 Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets
28 Sep 2017 Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
28 Sep 2017 Amgen And Simcere Announce Strategic Collaboration To Co-Develop And Commercialize Biosimilars In China
28 Sep 2017 Savara Announces Start of Pivotal Phase III AVAIL Study of AeroVanc
28 Sep 2017 TxCell collaboration presents new proof-of-concept transplantation results with proprietary second-generation CAR-Tregs
28 Sep 2017 MorphoSys and Galapagos Report First Promising Signs of Clinical Activity in a Phase 1 Study With IL-17C-Antibody MOR106 in Atopic Dermatitis Patients
27 Sep 2017 Medicago Announces Phase 3 Study of VLP Quadrivalent Influenza Vaccine
27 Sep 2017 Mateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer and Restructuring to Prioritize OXi4503 for AML
27 Sep 2017 Aduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD Based on Proprietary Neoantigen Technology
27 Sep 2017 Aduro Biotech Announces Advancement of ADU-S100 into Global Combination Trial With PDR001 for the Treatment of Solid Tumors and Lymphomas

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top